Abstract NQO1 participates in cellular defense against oxidative stress and regulates apoptosis via p53-and NFjB-mediated pathways. We have previously found that homozygous missense variant NQO1*2 (rs1800566) predicts poor survival among breast cancer patients, particularly after anthracycline-based adjuvant chemotherapy. Here, we investigated NQO1 and NFjB protein expression and global gene expression profiles in breast tumors with correlation to tumor characteristics and survival after adjuvant chemotherapy. We used immunohistochemical analysis of tissue microarrays to study NQO1 and NFjB expression in two series of tumors: 1000 breast tumors unselected for treatment and 113 from a clinical trial comparing chemotherapy regimens after anthracycline treatment in advanced breast cancer. We used gene expression arrays to define genes co-expressed with NQO1 and NFjB. NQO1 and nuclear NFjB were expressed in 83% and 11% of breast tumors, and correlated inversely (P = 0.012). NQO1 protein expression was associated with estrogen receptor (ER) expression (P = 0.011), whereas 34.5% of NFjB-nuclear/activated tumors were ER negative (P = 0.001). NQO1 protein expression and NFjB activation showed only trends, but no statistical significance for patient survival or outcome after anthracycline treatment. Gene expression analysis highlighted 193 genes that significantly correlated with both NQO1 and NFjB in opposite directions, consistent with the expression patterns of the two proteins. Inverse correlation was found with genes related to oxidation/reduction, lipid biosynthesis and steroid metabolism, immune response, lymphocyte activation, Jak-STAT signaling and apoptosis. The inverse relationship between NQO1 protein expression and NFjB Electronic supplementary material The online version of this article
Introduction
To improve individualized therapy, novel predictive markers are needed that identify patients with expected poor breast cancer outcome or patients who benefit most from a given treatment. We have recently shown that NAD(P)H: quinone oxidoreductase 1 homozygous genotype, NQO1*2, predicts poor survival among breast cancer patients, particularly after anthracycline-based adjuvant chemotherapy and in p53-aberrant tumors [1] . This functionally important common missense variant (rs1800566, c.558C[T) destabilizes NQO1 and cells homozygous for the mutant allele are deficient in NQO1 activity. Whereas the wild-type NQO1 protein is stable in cells, the variant form of NQO1 is rapidly turned over via ubiquitination followed by proteasomal degradation [2] [3] [4] . NQO1 is expressed in various normal tissues including breast and elevated NQO1 expression was reported for breast, ovarian, pancreatic, thyroid, adrenal, colon, and corneal cancer [5] [6] [7] .
NQO1 has multiple functions including protection against cytotoxicity and carcinogenicity of quinones and oxidative stress by catalyzing reduction and detoxification of quinone substrates [8, 9] . NQO1 plays a role in regulation of cell survival versus apoptosis through its interaction with p53 and links with the NFjB pathway. NQO1 regulates the stability of p53, protecting it from 20S proteasomal degradation. Active NQO1 increases the basal level and induction of p53, potentiating apoptosis especially in response to oxidative stress [10] [11] [12] . Its role in NFjB signalling is less clear. NFjB is a transcriptional regulator of NQO1, and NQO1 in turn regulates NFjB activation under certain conditions [13, 14] . While NFjB activation usually triggers cellular pro-survival, pro-proliferation responses, it can also lead to cell death [15] . The role of NQO1 in this context also varies from antiapoptotic to proapoptotic, possibly depending on cell type and/or microenvironmental factors. In mouse models the loss of NQO1 is accompanied by impaired function of NFjB, as TNF-a is unable to activate NFjB in NQO1-deficient mice. Moreover, it has been demonstrated that treating NQO1-wild-type cells with dicoumarol, an inhibitor of NQO1, abolishes TNF-induced NFjB activation [13, 16] . We have also previously shown that NQO1 enhances TNF-induced apoptosis in human breast tumors [1] , and a similar effect has been reported in breast carcinoma cells in vitro [17] .
Nuclearfactor kB (NFjB) is a transcription factor that is mostly cytoplasmic and translocates to nucleus upon activation [18] . While the basal level of active NFjB is minimal in most cell types, the constitutive activation of NFjB has been observed in various tumor types including human breast cancer [19] . Emerging evidence indicates the involvement of constitutively active NFjB in proliferation, angiogenesis, cell survival, metastasis, and apoptosis. For instance, in breast cancer cells, particularly with negative estrogen receptor status, NFjB activity is constitutive and thought to protect tumor cells against apoptosis [20, 21] . Indeed, elevated NFjB expression was suggested to associate with cancer cell resistance to radiation [22] and anthracycline-based chemotherapy [23] . Furthermore, while anthracycline-based treatment (doxorubicin) reportedly activates NFjB in cancer cells [24] , NFjB signaling induced by doxorubicin was also implicated in reduced expression of NFjB-dependent genes in cancer cells due to its instability in vivo [25] .
Here, we analyzed NQO1 protein expression and NFjB nuclear localization in an extensive series of sporadic and familial non-BRCA1/2 breast tumors and in a second series of primary breast tumors from patients in clinical trials comparing chemotherapy regimens after anthracycline treatment in advanced breast cancer, to investigate their correlation to clinical characteristics and breast cancer survival. Additionally, we used gene expression profiling to explore genes correlating with NQO1 and NFjB expression in human breast tumors.
Patients and methods
NQO1 and NFjB protein expression was analyzed in two series of invasive breast tumors. The first series included 884 tumors from unselected breast cancer patients and additional 542 familial cases. The unselected cases were ascertained at the Department of Oncology, Helsinki University Central Hospital, during the years 1997-1998 and 2000 as previously described [26, 27] . The additional 542 familial breast cancer cases were collected by a systematic screening at the Department of Oncology, Helsinki University Central Hospital or were ascertained through genetic counseling at the Department of Clinical Genetics. The total number of 1,238 invasive breast carcinomas were available for TMA as described [28] , including 423 from cases without familial background of breast cancer and 815 from patients with family history. Of the familial cases, 480 patients have strong family history of breast cancer (three or more first or second degree relatives with breast or ovarian cancer in the family, including the proband), and 335 had two affected first-degree relatives (including the proband). BRCA1 and BRCA2 mutations had been excluded from the familial patient series as described [29] [30] [31] .
Clinicopathological information on patients' characteristics, tumor size, nodal status, distant metastasis, estrogen and progesterone receptor status was collected from the pathology reports. A breast cancer pathologist (P.H.) re-reviewed all tumors for histological diagnosis and grade using the Scarff-Bloom-Richardson method, modified by Elston and Ellis [32] . Information on the tumor marker data used (p53, HER2, and ki-67) [33] [34] [35] [36] can be found in the Supplementary Note.
Information on adjuvant treatment and distant metastases during the follow-up was collected from the patient records. The information on death due to breast cancer or other reason was obtained from the Finnish Cancer Registry. Survival was calculated as 10 years overall survival (10 years OS): the time from diagnosis to the date of death due to breast cancer or other reasons, and as 5 years survival from metastasis to death: the time from distant metastasis to the date of death. Detailed information on the survival analysis can be found in the Supplementary Note.
The second series consists of 283 breast cancer patients with distant metastasis who participated in a randomized multicenter trial comparing taxotere (docetaxel) with methotrexate-fluorouracil (MF) after failure of anthracycline treatment in advanced breast cancer [37] . From these, 113 primary breast tumors on tissue microarrays (TMA) were available for our analysis. TMAs were prepared as described [38] . Response evaluation was performed according to the WHO recommendations [39] . Treatment response, time to progression (TTP), and overall survival (OS) from start of anthracycline treatment preceding randomization were analyzed. For statistical analysis, clinical response was divided into two categories: response (complete or partial) and non-response (no change and progression). Overall survival (AOS) was calculated from the start of anthracycline treatment until death. Time to progression (ATTP) was calculated from the start of anthracycline treatment till disease progression. AOS and ATTP data were available for 70 and 55 tumors stained for NQO1 and NFjB, respectively. Time to progression (TTP) on methotrexate-5-FU or docetaxel was measured from the date of randomization till disease progression. Of the 113 studied tumors, all were available and scored for NQO1, while 80 were available and scored for NFjB.
This study was done with patients' informed consent and permissions from the Ethics Committee of the Helsinki University Central Hospital and the Ministry of Social Affairs and Health in Finland. The study was performed according to reporting recommendations for tumor marker prognostic study (REMARK) [40] .
Immunohistochemistry
TMAs were constructed as described [28] , including four cores (diameter 0.6 mm) of the most representative area from each formalin-fixed and paraffin-embedded breast cancer specimen. For NQO1 analysis, TMA slides were stained with mouse monoclonal anti-human NQO1-antibody (Santa Cruz, diluted 1:500). For NFjB analysis, the TMAs were stained with rabbit monoclonal anti-human NFjB (ABCAM, diluted 1:1000). The secondary reagents were from Vector Laboratories (Burlingame, USA), and the chromogenic substrate enhancement step was performed as described, without nuclear counterstaining [41] . As only 0-1% of normal breast tissue or tumor cells were immunohistochemically positive for NQO1 in individuals with homozygous c.558C[T variant, we generally considered the breast tumors positive for NQO1 when 2% or more of the cancer cells were positive for NQO1 staining and negative when fewer than 2% were stained. For NFjB immunohistochemistry, a 5% cut-off was reported for nuclear staining in prostate cancer [42] . Consistently, we observed only rare nuclear positivity in normal or benign breast tissue (n = 30), and therefore we also considered NFjB as positive/activated in the breast carcinomas when 5% or more cancer cells showed nuclear staining and negative when fewer than 5% cells showed nuclear signal, or only cytoplasmic staining for NFjB.
Microarray data analysis
Total RNA was extracted from 183 primary breast tumors. The samples were processed and hybridized to Illumina HumanHT-12 v3 Expression BeadChips, containing 24660 Entrez Gene entities, according to the manufacturer recommendations (http://www.illumina.com).
Microarray raw data were imported into R (http:// cran.r-project.org) and processed by the methods included in the BioConductor facilities [43] . After quality control [44] , the data were normalized using the quantile method [45] and the gene expression matrix was obtained by averaging the probes mapping to the same Entrez Gene IDs [46] . The Pearson's correlation of each gene expression profile with the expression of NQO1 and NFjB1 was, respectively, calculated and the nominal P values were estimated. The genes with correlation P value \0.01 after Benjamini-Hochberg post hoc correction were further analyzed [47] . Functional annotation was performed on the NQO1-correlated and the NFjB1-correlated gene lists using the DAVID annotation tools [48] . The categories with Fisher's exact test P value \0.05 were considered to be significantly enriched.
Statistics
Statistical analyses were conducted in SPSS v15.0.1 for windows (SPSS, Inc.). The significance limit was set at 0.05. P values for evaluation of differences in NQO1 and/ or NFjB expression in varying tumor characteristics were calculated using Pearson's chi-squared tests or Fisher's exact test (for n \ 5). All P values are two sided. Log-rank tests were used to assess the statistical significance of differences between Kaplan-Meier curves for survival analyses among all patients. Univariate Cox's regression analyses were used to estimate relative risk in various subgroups. To ascertain the effect of differential NQO1protein expression on post-metastasis survival in the first series of patients, the beginning of follow-up time was set at date of diagnosed metastasis.
Results
We performed immunohistochemical analysis to study NQO1 and NFjB expression for association with tumor characteristics and survival in two series of breast cancer patients. NQO1 and NFjB staining results were obtained for 996 (80%) and 1030 (83%) tumors, respectively, from the first series of breast cancer patients. NQO1 expression and NFjB nuclear localization were seen in 83% and 11% of the tumors, respectively. There was no difference in the NQO1 expression or NFjB nuclear localization by family history background, therefore, all tumors were subsequently combined in the same analyses. From the second series of patients with metastatic disease, NQO1 and NFjB protein expression was obtained for 113 and 80 tumors, respectively. NQO1 was detected in 64% and NFjB nuclear localization in 15% of the analyzable tumors, respectively. Representative examples of NQO1 and p65 NFjB-staining pattern for normal human breast tissue and breast carcinomas with positive and negative NQO1 or NFjB expression are shown in Fig. 1 . The numbers of cases included in different analyses are shown in Supplementary Table 1 .
Association between NQO1 protein expression and clinico-pathological data There was an inverse correlation between NQO1 expression and NFjB nuclear localization/activation (P = 0.012). Furthermore, negative NQO1 was associated with ERnegativity (P = 0.011) but not with any other tumor characteristics. As expected, NQO1 staining correlated with the NQO1*2 homozygous variant genotype (P \ 0.0001). NQO1*2 homozygous (TT, Ser/Ser) cases were always NQO1 protein negative, whereas tumors from 171/264 (64%) of heterozygous patients and 541/573 (94%) of wildtype homozygous patients were positive for NQO1 immunostaining. Results of NQO1 protein expression in relation to tumor characteristics, NFjB activation, and NQO1*2 mutation status in the first breast cancer series are summarized in Table 1 .
In the second series of 113 patients treated with chemotherapy after metastatic disease, no significant association was observed between clinico-pathological data and NQO1 protein expression (Supplementary Table 2 ).
Association between NFjB activation and clinicopathological data
Tumor characteristics according to NFjB immunohistochemistry in the first series are shown in Table 2 . In addition to the inverse correlation with NQO1 expression, nuclear NFjB was associated with ductal histology (P = 0.017), ER-negativity (P = 0.001) and lower grade (P = 0.014).
In the second series of patients treated with chemotherapy for metastatic disease, no significant association to NFjB expression was detected (Supplementary Table 3 ).
Survival analyses
Survival analysis by NQO1 immunostaining did not show significant differences among all patients or in subgroups stratified by adjuvant chemotherapy treatment ( Fig. 2 ; Table 3 ). In the chemotherapy trial group, there were no Figure 1a- c; Table 4 ). However, patients with negative NQO1 expression had faster progression of the disease after second line methotrexate-fluorouracil treatment (P = 0.03, HR 1.99, 95% CI 1.04-3.78, Supplementary Figure 1d ; Table 4 ). NFjB protein localization/activation in tumors did not show any significant association with patient survival ( Fig. 3 ; Supplementary Figure 2 ). Although not statistically significant, NQO1 and NFjB protein expression showed tendency for inverse survival after adjuvant anthracycline treatment (reduced survival for patients with negative NQO1 or nuclear/activated NFjB). Analogous non-significant survival tendency was found in both patient series for overall survival, and for survival from metastasis to death and for time to tumor progression after anthracycline treatment in the chemotherapy trial series (Figs. 2, 3 ; Tables 3, 4) .
Microarray data analysis
In gene expression analysis, a total of 877 genes significantly correlated to NQO1 expression (293 positively and 584 negatively correlated) and 2,871 genes significantly correlated to NFjB1 expression (1,635 positively and Tables 4 and 5) . Interestingly, among genes correlating negatively with NQO1 expression are TNF and 12 other genes related to the TNF/NFjB pathway as well as 4 genes related to Toll-like receptor (TLR) family. Altogether, 193 genes were significantly correlated both with NQO1 and NFjB1. Only the gene LIMA1 positively correlated both with NQO1 and NFjB1, while all the other genes had inverse correlations with NQO1 and NFjB1: 59 genes correlated positively with NQO1 but negatively with NFjB1, while 133 genes correlated positively with NFjB1 but negatively with NQO1 (Supplementary Table 6 ). No genes showed concordant negative correlation both with NQO1 and NFjB1.
Opposite trends of the NQO1 and NFjB1-correlated genes were also observed when considering expression of functional gene families. The gene families of the endoplasmic reticulum, oxidation/reduction, lipid biosynthesis, and steroid metabolism were significantly over-represented both among the NQO1-positively correlated and NFjB1-negatively correlated genes. Furthermore, biological themes associated with immune response, lymphocyte activation, Jak-STAT signaling, and apoptosis were significantly over-represented among the NFjB1-positively correlated and NQO1-negatively correlated genes (Fig. 4) . Similar functional profiles were represented by the 193 NQO1-and NFjB1-commonly correlated genes (Supplementary Table 7 ).
Discussion
We have applied immunohistochemistry to study expression of NQO1 and nuclear localization of NFjB in two series of human breast tumors, with correlation to tumor characteristics and survival and tumor progression after adjuvant chemotherapy. We found an inverse correlation between NQO1 expression and NFjB nuclear localization, with correlation of NQO1 expression with ER-positive tumors and NFjB nuclear expression with ER-negative tumors. The gene expression profiling corroborated and extended the opposing effects of NQO1 and NFjB expression observed by the immunohistochemistry analysis. Interestingly, among genes which negatively correlated with NQO1 are TNF, TNF-related genes and TLR-related genes. Both families promote NFjB nuclear import [49] . NQO1 gene expression correlated positively and NFjB gene expression negatively with genes implicated in cellular processes of oxidation/reduction, lipid biosynthesis, and steroid metabolism whereas the opposite correlation was found for biological themes associated with immune response, lymphocyte activation, Jak-STAT signaling and apoptosis, consistent with the published functions of NQO1 and NFjB. The association between NQO1 and ER expression was not unexpected, given the role of NQO1 in estrogen metabolism and the fact that NQO1 is in part transcriptionally regulated by ER [50] . Indeed, our gene expression analysis shows that several genes involved in steroid metabolism are co-upregulated with NQO1 in breast tumors. On the other hand, NFjB nuclear expression was more common in ER-negative tumors, consistent with previous data [51] . ER and NFjB reportedly mutually repress each other, in addition to which there may be functional differences in NFjB signalling depending on ER status [52] . These findings are thus anticipated in view of previous literature. In contrast, the inverse relationship between NQO1 protein expression and NFjB activation is a novel finding, and somewhat unexpected given that they have been shown to be commonly co-activated in both normal and malignant cells, even upregulating each other [13, 14, 16, 53] . In melanoma, NQO1-mediated NFjB activation (through stabilization of BCL3) may drive cell cycle progression and proliferation [54] . This disparity between breast cancer and other malignancies and tissues might reflect ER signalling in breast cancer. Given the documented mutual repression between ER and NFjB and the ability of ER to induce NQO1, it may be that the effects of ER override the mutual regulation between NQO1 and NFjB. Subgroup analyses of the association between NQO1 and NFjB in ER-positive and -negative cases separately (data not shown) unfortunately could not resolve this issue due to lack of statistical power especially in the smaller ER-negative group. In any case, it would appear that the NQO1-NFjB interaction in breast cancer differs from several other tissues, and functional elucidation of the underlying causal mechanism could provide insight into the biology of breast cancer and, potentially, its treatment.
In our previous study, we have found a strong association of the variant genotype NQO1*2 with poor prognosis of breast cancer patients, especially those treated with anthracycline-based chemotherapy. The homozygous patients showed increased mortality and reduced median survival time also after detection of metastasis suggesting resistance to treatment of the metastatic cells [1] . Here, we evaluated whether also NQO1 protein expression associates with patient survival in general and in treatment subgroups specifically. The results from this study suggest that NQO1 expression, or NFjB activation, do not appear to be given sample might not indicate that the cells are unable to express NQO1 in response to treatment, for example, but merely that the signalling event was not taking place when the sample was taken, or that the expression level is below detection threshold. Additionally, there does not appear to be strong selective pressure to lose the wild-type allele of NQO1 in breast tumors; in fact, the variant 609T allele was reportedly more commonly lost [57] . We observed no difference in genomic copy number of the region including NQO1 gene (16q22) between tumors from the normal wildtype, heterozygous, or homozygous NOQ1*2 variant carriers (data not shown) [58] further suggesting that the wildtype allele may be retained in the heterozygous carrier tumors, or not lost at least by genomic mechanisms. Given the lack of apparent LOH pressure, and the fact that NQO1 expression and NFjB activation were inversely correlated but not mutually exclusive, it is possible that the mutual upregulation between NQO1 and NFjB, as documented in other studies, could also occur in some breast tumors. This could have separate impact on survival and treatment response, and might confound survival analyses stratified by NQO1 immunohistochemistry alone. Discovering such subgroups in a survival analysis would however require a very large sample set. Despite the lack of support for NQO1 (or NFjB) immunohistochemistry as prognostic or predictive markers, we observed that in the second series of patients treated with chemotherapy for metastatic disease, negative NQO1 immunostaining associated with faster disease progression after methotrexate-fluorouracil treatment following failure of anthracycline-based chemotherapy. This finding may suggest a pattern of differential association between NQO1 expression and response to various types of treatment, but lack of statistical power prevents a more granular analysis of the current material. We can speculate that NQO1*2 homozygotes are enriched in the anthracycline-resistant series, consistent with the higher frequency of tumors with negative NQO1 expression in this series, or that induction of NQO1 was lost by some other mechanism in advanced breast cancer due to treatment-related selective pressure. Very large studies are needed to further investigate association of NQO1 expression, preferably with available NQO1*2 genotype data, with the outcome of combined or sequential treatment with different chemotherapy agents.
